Latest Posts
About This Stock
More About This Stock
Read
Read
Read
Alkermes Targets Bipolar Disorder And Schizophrenia
Article By:
MoneyShow.com
Sunday, February 16, 2020 11:52 AM EDT
We strongly recommend that investors take advantage of the weakness and buy Alkermes, whose treatment of schizophrenia and bipolar disorder has been accepted by the FDA for review.
Key FDA Events In June Investors Need To Watch Out For
Article By:
Zacks Investment Research
Sunday, June 3, 2018 12:49 PM EDT
It has been a busy year for the FDA so far with the agency approving 14 drugs. The approval of these drugs should boost their respective companies’ top line as a few of them are struggling with decline in sales of legacy drugs.
Alkermes Rises After Nektar Said To Explore Sale
Article By:
The Fly
Friday, February 2, 2018 4:12 PM EDT
Shares of Alkermes have been rising this afternoon after Bloomberg reported that another drugmaker exploring some of the same therapeutic areas, Nektar Therapeutics, is exploring its strategic options, including a potential sale.